Capital Insights
The Private Equity Signal I Am Watching Very Closely
Pattern recognition in private markets is not about predicting the future. It is about reading what is already moving before the wider market notices. I spotted the same signal in life sciences 18 months before it became consensus. We are watching it happen again, this time in private equity.
The Australian Life Science Sector: A Structural Convergence of 5 Critical Factors
For a decade, we have watched the foundation being built. Government grants are flowing into research infrastructure. Labs constructed. IP portfolios are growing. Talent returning from global pharma. For most of that decade, the returns were slow, the timelines were long, and the capital was cautious. That era is over. The Australian life science sector […]
The Private Capital Infrastructure Is Failing High-Growth Companies
The Broken Reality of Capital Raising Infrastructure Venture capital poured 55% of global funding into AI companies in 2025. Seed and Series A rounds saw 70% of capital flow to AI-related opportunities. The capital is available. The demand is clear. But the infrastructure connecting founders to investors remains unchanged. Deal flow arrives through LinkedIn messages, […]
What Active Private Market Investors Told Us They Want in 2026
We just released the 2026 Investor Survey, the most comprehensive look at what private market investors are actually thinking and prioritizing as they deploy capital this year. Key data challenges assumptions, revealing that nearly 68% of the active investor base are individuals, not institutions.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
The Silent Trigger: How Biotome is Dismantling the World’s Fourth Deadliest Cancer
Biotome is transforming gastric cancer detection through precision immunology. Their flagship test Helitope uses peptide augmentation to target specific bacterial markers, delivering 10 times greater sensitivity and 95% accuracy compared to traditional diagnostic tests.
The Endocannabinoid Entrepreneurs: Inside Medigrowth’s Mission to Mainstream Plant-Based Medicine
Medigrowth is transforming the Australian cannabis landscape from a “wild west” into a clinically-led biotech powerhouse. Led by founders Adam Guskich and Todd McClellan, the company is leveraging university-led research to target a multi-billion dollar unmet need in chronic conditions including pain and mental health.
Vision Via Sound for the Blind: Can a Silicon Valley Veteran Deliver the Solution to a $2B NDIS Problem?
Serial entrepreneur Robert Yearsley is trading pixels for perception with ARIA Research, a Sydney-based deep-tech company using “augmented reality in audio” to help the blind perceive the world. By bypassing traditional bionics in favour of real-time 3D soundscapes, ARIA is tackling a multi-billion dollar unmet need in the global disability sector and redefining what it means to “see” without eyesight.
Private Credit Is No Longer Just a Defensive Play. Here Is What Investors Actually Want.
Private credit is no longer just a defensive allocation. Based on our 2026 Investor Survey, the largest segment of investors (44%) now wants hybrid structures that combine yield with equity optionality, demanding that fund managers rethink how credit products are structured, positioned, and sold.
Backed By Leading Investment Groups and Family Offices
